Wealthstream Advisors Inc. Buys 209 Shares of Johnson & Johnson (NYSE:JNJ)

Wealthstream Advisors Inc. raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 11.4% in the third quarter, Holdings Channel reports. The fund owned 2,039 shares of the company’s stock after purchasing an additional 209 shares during the quarter. Wealthstream Advisors Inc.’s holdings in Johnson & Johnson were worth $333,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in JNJ. Morton Brown Family Wealth LLC lifted its holdings in shares of Johnson & Johnson by 78.0% in the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after acquiring an additional 78 shares during the last quarter. Goodman Advisory Group LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at approximately $39,000. Cardinal Capital Management Inc. raised its holdings in Johnson & Johnson by 333.3% in the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after buying an additional 200 shares during the last quarter. First Bank & Trust raised its holdings in Johnson & Johnson by 69.6% in the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after buying an additional 156 shares during the last quarter. Finally, Heritage Wealth Management LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at approximately $84,000. Institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $173.43 on Tuesday. The company has a market cap of $453.43 billion, a price-to-earnings ratio of 24.15, a price-to-earnings-growth ratio of 3.28 and a beta of 0.56. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The firm has a 50 day moving average of $176.33 and a 200-day moving average of $171.44.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. During the same quarter last year, the firm posted $2.60 EPS. The company’s quarterly revenue was up 1.9% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.61%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 62.95%.

Insider Buying and Selling

In related news, VP Peter Fasolo sold 22,864 shares of the stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now directly owns 114,676 shares in the company, valued at approximately $18,864,202. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Johnson & Johnson news, insider William Hait sold 15,000 shares of the firm’s stock in a transaction on Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the transaction, the insider now directly owns 80,236 shares in the company, valued at approximately $13,764,485.80. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Peter Fasolo sold 22,864 shares of the firm’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total value of $3,761,128.00. Following the transaction, the vice president now owns 114,676 shares in the company, valued at $18,864,202. The disclosure for this sale can be found here. Insiders have sold a total of 300,750 shares of company stock worth $52,311,677 in the last ninety days. Corporate insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Credit Suisse Group assumed coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective for the company. StockNews.com assumed coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Sanford C. Bernstein dropped their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Raymond James decreased their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Finally, Atlantic Securities decreased their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Seven equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $182.42.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.